Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Special Feature Articles - Most Recent
    • Special Features
    • Colloquia
    • Collected Articles
    • PNAS Classics
    • List of Issues
  • Front Matter
    • Front Matter Portal
    • Journal Club
  • News
    • For the Press
    • This Week In PNAS
    • PNAS in the News
  • Podcasts
  • Authors
    • Information for Authors
    • Editorial and Journal Policies
    • Submission Procedures
    • Fees and Licenses
  • Submit
  • Submit
  • About
    • Editorial Board
    • PNAS Staff
    • FAQ
    • Accessibility Statement
    • Rights and Permissions
    • Site Map
  • Contact
  • Journal Club
  • Subscribe
    • Subscription Rates
    • Subscriptions FAQ
    • Open Access
    • Recommend PNAS to Your Librarian

User menu

  • Log in
  • My Cart

Search

  • Advanced search
Home
Home
  • Log in
  • My Cart

Advanced Search

  • Home
  • Articles
    • Current
    • Special Feature Articles - Most Recent
    • Special Features
    • Colloquia
    • Collected Articles
    • PNAS Classics
    • List of Issues
  • Front Matter
    • Front Matter Portal
    • Journal Club
  • News
    • For the Press
    • This Week In PNAS
    • PNAS in the News
  • Podcasts
  • Authors
    • Information for Authors
    • Editorial and Journal Policies
    • Submission Procedures
    • Fees and Licenses
  • Submit
Research Article

The circadian clock protein REVERBα inhibits pulmonary fibrosis development

Peter S. Cunningham, Peter Meijer, Alicja Nazgiewicz, Simon G. Anderson, Lee A. Borthwick, James Bagnall, View ORCID ProfileGareth B. Kitchen, Monika Lodyga, Nicola Begley, Rajamiyer V. Venkateswaran, Rajesh Shah, Paul F. Mercer, Hannah J. Durrington, Neil C. Henderson, Karen Piper-Hanley, Andrew J. Fisher, Rachel C. Chambers, David A. Bechtold, Julie E. Gibbs, Andrew S. Loudon, Martin K. Rutter, Boris Hinz, View ORCID ProfileDavid W. Ray, and View ORCID ProfileJohn F. Blaikley
  1. aFaculty of Biology, Medicine and Health, The University of Manchester, Manchester M13 9PL, United Kingdom;
  2. bThe George Alleyne Chronic Disease Research Centre, The University of the West Indies, Bridgetown. Barbados BB11000;
  3. cFibrosis Research Group, Biosciences Institute, Newcastle University, Newcastle upon Tyne NE2 4HH, United Kingdom;
  4. dManchester University National Health Service Foundation Trust, Manchester Academic Health Science Centre, Manchester M13 9WL, United Kingdom;
  5. eLaboratory of Tissue Repair and Regeneration, Faculty of Dentistry, University of Toronto, Toronto, ON M5G 1G6, Canada;
  6. fCentre for Inflammation and Tissue Repair, Faculty of Medical Sciences, University College London, London WC1E 6JJ, United Kingdom;
  7. gCentre for Inflammation Research, University of Edinburgh, EH16 4TJ Edinburgh, United Kingdom;
  8. hInstitute of Transplantation, Freeman Hospital, The Newcastle upon Tyne Hospitals National Health Service Foundation Trust, Newcastle upon Tyne NE7 7DN, United Kingdom;
  9. iTranslational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne NE2 4HH, United Kingdom;
  10. jNational Institute for Health Research Oxford Biomedical Research Centre, John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom;
  11. kOxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford OX3 7LE, United Kingdom

See allHide authors and affiliations

PNAS January 14, 2020 117 (2) 1139-1147; first published December 26, 2019; https://doi.org/10.1073/pnas.1912109117
Peter S. Cunningham
aFaculty of Biology, Medicine and Health, The University of Manchester, Manchester M13 9PL, United Kingdom;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Meijer
aFaculty of Biology, Medicine and Health, The University of Manchester, Manchester M13 9PL, United Kingdom;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alicja Nazgiewicz
aFaculty of Biology, Medicine and Health, The University of Manchester, Manchester M13 9PL, United Kingdom;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Simon G. Anderson
aFaculty of Biology, Medicine and Health, The University of Manchester, Manchester M13 9PL, United Kingdom;
bThe George Alleyne Chronic Disease Research Centre, The University of the West Indies, Bridgetown. Barbados BB11000;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lee A. Borthwick
cFibrosis Research Group, Biosciences Institute, Newcastle University, Newcastle upon Tyne NE2 4HH, United Kingdom;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James Bagnall
aFaculty of Biology, Medicine and Health, The University of Manchester, Manchester M13 9PL, United Kingdom;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gareth B. Kitchen
aFaculty of Biology, Medicine and Health, The University of Manchester, Manchester M13 9PL, United Kingdom;
dManchester University National Health Service Foundation Trust, Manchester Academic Health Science Centre, Manchester M13 9WL, United Kingdom;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Gareth B. Kitchen
Monika Lodyga
eLaboratory of Tissue Repair and Regeneration, Faculty of Dentistry, University of Toronto, Toronto, ON M5G 1G6, Canada;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicola Begley
aFaculty of Biology, Medicine and Health, The University of Manchester, Manchester M13 9PL, United Kingdom;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rajamiyer V. Venkateswaran
dManchester University National Health Service Foundation Trust, Manchester Academic Health Science Centre, Manchester M13 9WL, United Kingdom;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rajesh Shah
dManchester University National Health Service Foundation Trust, Manchester Academic Health Science Centre, Manchester M13 9WL, United Kingdom;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul F. Mercer
fCentre for Inflammation and Tissue Repair, Faculty of Medical Sciences, University College London, London WC1E 6JJ, United Kingdom;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hannah J. Durrington
aFaculty of Biology, Medicine and Health, The University of Manchester, Manchester M13 9PL, United Kingdom;
dManchester University National Health Service Foundation Trust, Manchester Academic Health Science Centre, Manchester M13 9WL, United Kingdom;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Neil C. Henderson
gCentre for Inflammation Research, University of Edinburgh, EH16 4TJ Edinburgh, United Kingdom;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karen Piper-Hanley
aFaculty of Biology, Medicine and Health, The University of Manchester, Manchester M13 9PL, United Kingdom;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew J. Fisher
hInstitute of Transplantation, Freeman Hospital, The Newcastle upon Tyne Hospitals National Health Service Foundation Trust, Newcastle upon Tyne NE7 7DN, United Kingdom;
iTranslational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne NE2 4HH, United Kingdom;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rachel C. Chambers
fCentre for Inflammation and Tissue Repair, Faculty of Medical Sciences, University College London, London WC1E 6JJ, United Kingdom;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David A. Bechtold
aFaculty of Biology, Medicine and Health, The University of Manchester, Manchester M13 9PL, United Kingdom;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julie E. Gibbs
aFaculty of Biology, Medicine and Health, The University of Manchester, Manchester M13 9PL, United Kingdom;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew S. Loudon
aFaculty of Biology, Medicine and Health, The University of Manchester, Manchester M13 9PL, United Kingdom;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin K. Rutter
aFaculty of Biology, Medicine and Health, The University of Manchester, Manchester M13 9PL, United Kingdom;
dManchester University National Health Service Foundation Trust, Manchester Academic Health Science Centre, Manchester M13 9WL, United Kingdom;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Boris Hinz
eLaboratory of Tissue Repair and Regeneration, Faculty of Dentistry, University of Toronto, Toronto, ON M5G 1G6, Canada;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David W. Ray
aFaculty of Biology, Medicine and Health, The University of Manchester, Manchester M13 9PL, United Kingdom;
jNational Institute for Health Research Oxford Biomedical Research Centre, John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom;
kOxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford OX3 7LE, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for David W. Ray
John F. Blaikley
aFaculty of Biology, Medicine and Health, The University of Manchester, Manchester M13 9PL, United Kingdom;
dManchester University National Health Service Foundation Trust, Manchester Academic Health Science Centre, Manchester M13 9WL, United Kingdom;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for John F. Blaikley
  • For correspondence: john.blaikley@manchester.ac.uk
  1. Edited by Joseph S. Takahashi, The University of Texas Southwestern Medical Center, Dallas, TX, and approved November 22, 2019 (received for review July 16, 2019)

  • Article
  • Figures & SI
  • Info & Metrics
  • PDF
Loading

Significance

The circadian clock plays an essential role in energy metabolism and inflammation. In contrast, the importance of the clock in the pathogenesis of fibrosis remains poorly explored. This study describes a striking alteration in circadian biology during pulmonary fibrosis where the relatively arrhythmic alveolar structures gain circadian but asynchronous rhythmicity due to infiltration by fibroblasts. Disruption of the clock in these cells, which are not widely implicated in circadian pathophysiology, results in a profibrotic phenotype. Translation of these findings in humans revealed previously unrecognized important circadian risk factors for pulmonary fibrosis (sleep length, chronotype, and shift work). In addition, targeting REVERBα repressed collagen secretion from human fibrotic lung tissue, making this protein a promising therapeutic target.

Abstract

Pulmonary inflammatory responses lie under circadian control; however, the importance of circadian mechanisms in the underlying fibrotic phenotype is not understood. Here, we identify a striking change to these mechanisms resulting in a gain of amplitude and lack of synchrony within pulmonary fibrotic tissue. These changes result from an infiltration of mesenchymal cells, an important cell type in the pathogenesis of pulmonary fibrosis. Mutation of the core clock protein REVERBα in these cells exacerbated the development of bleomycin-induced fibrosis, whereas mutation of REVERBα in club or myeloid cells had no effect on the bleomycin phenotype. Knockdown of REVERBα revealed regulation of the little-understood transcription factor TBPL1. Both REVERBα and TBPL1 altered integrinβ1 focal-adhesion formation, resulting in increased myofibroblast activation. The translational importance of our findings was established through analysis of 2 human cohorts. In the UK Biobank, circadian strain markers (sleep length, chronotype, and shift work) are associated with pulmonary fibrosis, making them risk factors. In a separate cohort, REVERBα expression was increased in human idiopathic pulmonary fibrosis (IPF) lung tissue. Pharmacological targeting of REVERBα inhibited myofibroblast activation in IPF fibroblasts and collagen secretion in organotypic cultures from IPF patients, thus suggesting that targeting of REVERBα could be a viable therapeutic approach.

  • pulmonary fibrosis
  • circadian
  • Reverb alpha
  • sleep
  • integrin

The circadian clock in the lung drives important physiological responses, including temporal gating of a number of inflammatory (1⇓–3) and antioxidant responses (4). Key cell types that are known to be important are the nonciliated, bronchial epithelial cells (club cells) (2) and alveolar macrophages (3, 5). In contrast, alveolar structures typically exhibit weak circadian oscillations (6). Genetic disruption of the Clock gene (4) impairs circadian pulmonary oscillations and leads to exaggerated pulmonary responses to bleomycin challenge, a model of pulmonary fibrosis (7).

Pulmonary fibrosis, including idiopathic pulmonary fibrosis (IPF), is frequently fatal with existing treatments slowing progression rather than curing the disease (8). The causes and nongenetic risk factors for IPF are poorly understood, with several studies implicating age, sex, smoking, and more recently air pollution (9). IPF is characterized histologically by the development of fibroblastic foci in the lung parenchyma (10). Cells in these foci are typically activated myofibroblasts (11) derived from multiple sources (12, 13), including pulmonary fibroblasts and pericytes (11, 14). Myofibroblasts secrete collagen, resulting in abnormal lung function and are characterized by increased focal-adhesion formation and acquisition of a contractile cytoskeleton with alpha smooth muscle actin (αSMA)-positive stress fibers (15). In addition to fibroblasts, pulmonary fibrosis involves other cell types, e.g., club cells (9) and macrophages (16), regulating the accumulation of fibroblasts and therefore the deposition of the extracellular matrix. As these cell types maintain autonomous circadian oscillations (2, 5), examination of circadian factors and mechanisms in the pulmonary fibrotic response is warranted.

The circadian clock operates as a cell-autonomous timing mechanism (17), allowing temporal segregation of both physiological and pathophysiological programs (18, 19). At the cellular level, the circadian clock consists of a transcription–translation feedback loop (20), in which the positive elements CLOCK and BMAL1 drive expression of 2 negative-feedback arms controlled by PERIOD/CRYPTOCHROME (PER/CRY) and the 2 paralogs, REVERBα and REVERBβ. In turn, these negative-feedback arms repress BMAL1/CLOCK heterodimer transactivation function (PER/CRY) or BMAL1 expression (REVERBα/β). The resulting 24-h oscillations in protein expression can be disrupted through environmental disruption (e.g., shift-work schedules) or genetic deletion of core clock components, producing inflammatory and metabolic phenotypes (5, 21, 22).

Here, we show that fibrotic mouse lungs exhibited amplified, but asynchronous, circadian rhythms with a dominant role for myofibroblasts. Disruption of the core clock protein REVERBα in fibroblastic cells resulted in exaggerated pulmonary fibrotic response to bleomycin in mice. In culture, REVERBα knockdown resulted in increased myofibroblast differentiation via the transcription factor TBPL1, through alteration of formation of integrinβ1 focal-adhesion expression. Furthermore, exposure to circadian stresses such as late chronotype, shift work, and altered sleep duration are all associated with IPF, and clock-gene expression is altered in IPF versus normal human lung. Targeting of REVERBα by a synthetic ligand repressed myofibroblast differentiation and collagen secretion in cultured fibroblasts and lung slices obtained from patients with lung fibrosis.

Results

Myofibroblasts Drive High-Amplitude, but Asynchronous, Circadian Oscillations in Fibrotic Lung.

Precision-cut lung slices (PCLS) from transgenic mPER2::LUC mice (2) were used to track circadian oscillations in real time after bleomycin induction of fibrosis (Fig. 1 A and B, SI Appendix, Fig. S1 A and B, and Movie S1). Fibrotic areas were identified by loss of lung architecture in the bright-field image and confirmed with increased collagen deposition when the slices were fixed for histology (SI Appendix, Fig. S1 A and B). The amplitude of PER2 oscillations in the fibrotic areas was increased compared to nonfibrotic parenchyma lung (Fig. 1 A–D). This fibrotic parenchyma also had a greater degree of phase asynchrony compared to regions in the nonfibrotic parenchyma (Fig. 1C) but retained the same overall 24-h period (SI Appendix, Fig. S1C). One possible explanation may relate to changes in cell density in the fibrotic parenchyma. To explore this, PCLS were stained with Hoechst. There was a greater intensity of staining in fibrotic areas compared to nonfibrotic areas, but this did not correlate with bioluminescence (SI Appendix, Fig. S1 D–F). Another possible explanation is infiltration by a more rhythmic cell type; therefore, we deleted the essential core clock component BMAL1 (23) in both fibroblasts and club cells to ablate cell-autonomous rhythms. BMAL1 deletion in club cells (CCSP-Bmal1−/−), the main oscillatory cells in the lung (6), had no effect on the increased amplitude seen in fibrotic regions (Fig. 1 D and G, SI Appendix, Fig. S2A, and Movie S2). In contrast, BMAL1 deletion in pericyte/fibroblast lineage (Pdgfrb-Bmal1−/−) restored the amplitude of lung oscillations in fibrotic lung to levels measured in unaffected lung tissue (Fig. 1 E–G, SI Appendix, Fig. S2B, and Movie S3).

Fig. 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 1.

Asynchronous circadian oscillations occur in pulmonary fibrosis. (A) Bioluminescent image along with heat maps of amplitude and phase taken from the same PCLS obtained from a mPER2::luc mouse 14 d after in vivo bleomycin treatment (3 U/kg). Data are representative of 3 separate experiments. (Scale bars, 500 µm.) (B) Bioluminescent intensity plotted against time for both parenchyma and bronchioles in fibrotic and nonfibrotic regions (data are representative of 3 separate experiments). (C) Time to first peak for bronchioles and parenchyma in fibrotic and nonfibrotic areas. *P < 0.05 (ANOVA with post hoc Dunnett test using 18, 19, and 48 representative sections for healthy airways, fibrotic airways, and fibrotic parenchyma, respectively, in the lung slice). Data are representative of 3 separate experiments (mean ± SEM). (D) Bioluminescent intensity plotted against time (24-h moving average baseline subtracted) for the representative slices shown in A and Ccsp-Bmal1−/− mice shown in SI Appendix, Fig. S2A. (E) Representative bioluminescent image along with bioluminescent intensity plotted against time for a PCLS 14 d after in vivo bleomycin treatment in the Pdgfrb-Bmal1−/− mPER2::luc mouse (3 U/kg). Data are representative of 3 separate experiments. (Scale bar, 500 µm.) (F) Bioluminescent intensity plotted against time (24-h moving average baseline subtracted) for the Pdgfrb-Bmal1−/− representative slice shown in E. (G) Difference in bioluminescence between fibrotic and nonfibrotic parenchyma over 3 d in PCLS from WT, Ccsp-Bmal1−/−, and Pdgfrb-Bmal1−/− mice after in vivo bleomycin treatment (n = 3 animals). ns, not significant. *P < 0.05 (1-way ANOVA Dunnett post hoc test; mean ± SEM).

To test if fibrotic factors are capable of modifying circadian signals, lung slices and fibroblasts were treated with TGFβ. TGFβ induced changes in circadian phase (SI Appendix, Fig. S3A), with the magnitude of effect being dependent on both concentration and circadian phase (SI Appendix, Fig. S3 B and C). Lung physiology is also changed in fibrosis, resulting in an altered mechanoenvironment (24). Since tensile strength has recently been shown to play a key role in the regulation of tissue-based circadian rhythms (25), we investigated whether lung inflation, a cause of increased mechanical stretch, influenced circadian oscillations. Here, PER2 oscillation amplitude was increased in inflated lungs compared to noninflated controls, demonstrating that changes to the local mechanoenvironment may alter circadian oscillations (SI Appendix, Fig. S3D).

REVERBα in Fibroblasts Suppresses the Development of Pulmonary Fibrosis.

REVERBα is an orphan nuclear receptor and operates both as an essential core clock factor and as a major clock output pathway. Its function can be disrupted by deletion of its DNA-binding domain, and small molecular ligands are available to modulate activity. Therefore, we deleted the REVERBα DNA-binding domain (Fig. 2A), under Pdgfrb control (26). This resulted in an exaggerated fibrotic response (Fig. 2 B and C) and increased accumulation of αSMA-positive myofibroblasts in response to bleomycin (Fig. 2 D and E). Wild-type (WT) and transgenic mice did not differ in lung parameters following saline inoculation (Fig. 2 B and E and SI Appendix, Fig. S4 A and B). Importantly, REVERBα genetic disruption in myelomonocytic cells or bronchial epithelial cells did not affect the development of the fibrotic phenotype (SI Appendix, Fig. S4 C and D).

Fig. 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 2.

REVERBα alters susceptibility to pulmonary fibrosis through its effect on myofibroblast differentiation. (A) Schematic showing generation of Pdgfrb-Reverbα−/− mice combined with qPCR analysis of Reverbα expression in lung fibroblasts (n = 3 animals). **P < 0.01 (Student t test; mean ± SEM). (B) Hydroxyproline measurement in lungs from Pdgfrb-Reverbα−/− mice and littermate controls 28 d following challenge with intratracheal bleomycin (2 U/kg) or saline (n = 4 to 5 saline and 8 bleomycin per genotype). *P < 0.05; **P < 0.01 (2-way ANOVA Holm–Sidak post hoc test; mean ± SEM). (C) In a separate experiment, histology (Picrosirius red) of lungs was examined 28 d following challenge with intratracheal bleomycin (representative image from 4 animals treated with bleomycin per genotype). (Scale bars, 200 µm.) (D) Immunohistochemical staining of myofibroblasts (anti-αSMA, 3,3′-diaminobenzidine [DAB]) from Pdgfrb-Reverbα−/− mice and littermate controls 28 d following intratracheal bleomycin challenge (representative image from 4 animals treated with bleomycin per genotype). (Scale bars, 200 µm.) (E) Histological scoring (grade 0 to 4) for the presence of αSMA staining 28 d following intratracheal bleomycin challenge (n = 3 saline and 4 to 5 bleomycin per genotype). *P < 0.05 (2-way ANOVA Holm–Sidak post hoc test; mean ± SEM). (F and G) Representative immunofluorescence images of primary lung fibroblast cultures from Pdgfrb-Reverbα−/− mice and littermate controls showing intracellular αSMA (red) (n = 3 animals per genotype) (F) combined with a representative immunoblot and quantification of intracellular αSMA from primary lung fibroblast cultures (n = 4 animals per genotype) (G). *P < 0.05 (Student t test; mean ± SEM). DAPI, 4′,6-diamidino-2-phenylindole. (Scale bars in F, 10 µm.) (H) Representative collagen-1 ECM (extracellular matrix) images and quantification following culture of Pdgfrb-Reverbα−/− and Reverbαfl/fl primary lung fibroblasts (n = 3 animals per genotype). *P < 0.05 (Student t test; mean ± SEM). (Scale bars, 50 µm.) (I) Schematic illustrating the action of REVERBα in inhibiting fibroblast/myofibroblast differentiation. FAs, focal adhesions.

Characterization of primary fibroblasts explanted from Pdgfrb-Reverbα−/− lungs ex vivo revealed increased expression of αSMA and increased secretion of collagen-1, markers of myofibroblast activation (Fig. 2 F–H). This indicates a fibroblast-intrinsic change driven by disruption of REVERBα, with culture on hard plastic providing the environmental trigger for initiation of the myofibroblast differentiation program (Fig. 2I).

Knockdown of REVERBα in Vitro Enhances Myofibroblast Activation through the Transcription Factor TBPL1.

Next, we set out to identify REVERBα gene targets using small interfering RNA (siRNA) knockdown of REVERBα in both mouse and human lung fibroblast cell lines (SI Appendix, Fig. S5A). REVERBα knockdown resulted in myofibroblast activation in lung fibroblast cells (Fig. 3 A and B and SI Appendix, Fig. S5 B–D). Although many genes were regulated by REVERBα knockdown, only 3 (including Reverbα) were consistently repressed at both time points (12 and 24 h) and in both cell lines (Fig. 3C and SI Appendix, Fig. S5 E and F). One was Plod2, a proline hydroxylase required for collagen processing. The second was Tbpl1, a relatively uncharacterized transcription factor. Knockdown of either PLOD2 or TBPL1 did not affect REVERBα expression (SI Appendix, Fig. S6A). In addition, knockdown of PLOD2 repressed αSMA expression, therefore making it an unlikely downstream mediator of the REVERBα effect (SI Appendix, Fig. S6B). Therefore, we turned to TBPL1 and verified loss of protein expression with REVERBα knockdown (Fig. 3D). Knockdown of TBPL1 caused a similar induction of αSMA expression to that seen with REVERBα knockdown (Fig. 3E), suggesting that REVERBα and TBPL1 may lie on the same pathway.

Fig. 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 3.

REVERBα alters myofibroblast differentiation via TBPL1. (A) Immunofluorescent staining and quantification for the myofibroblast marker αSMA after control (nontargeting) or Reverbα siRNA knockdown in mLF-hT cells (n = 3 separate transfections). *P < 0.05 (Student t test; mean ± SEM). (Scale bars, 50 µm.) (B) Immunoblot and densitometry for αSMA in MRC-5 cells after control (nontargeting) or REVERBα siRNA knockdown (representative immunoblot shown; n = 3 separate transfections). *P < 0.05 (Student t test; mean ± SEM). (C) Schematic of RNA-seq sample preparation. Control (nontargeting) or Reverbα siRNA knockdown was performed in 2 fibroblast cell lines (mLF-hT cells and MRC-5). Samples were collected for RNA-seq analysis 12 and 24 h after siRNA transfection from 3 separate transfections for each cell line per time point. Pooled analysis of all 4 different RNA-seq experimental conditions is shown by a volcano plot (mean fold change plotted against mean q-value). (D) Immunoblot of TBPL1 following control (nontargeting) or Reverbα or Tbpl1 siRNA knockdown in mLF-hT cells (a representative immunoblot is shown; n = 3 separate transfections). **P < 0.01 (Student t test; mean ± SEM). (E) Representative immunofluorescence and immunoblotting for αSMA after control (nontargeting) or Tbpl1 siRNA knockdown in mLF-hT cells (a representative immunoblot is shown; n = 3 separate transfections). *P < 0.05 (Student t test; mean ± SEM). (Scale bars, 50 µm.) DAPI, 4′,6-diamidino-2-phenylindole.

REVERBα and TBPL1 Regulate Integrinβ1 Expression.

To decipher how REVERBα and/or TBPL1 suppress myofibroblast activation in fibrotic lungs and in the stiff cell culture environment, we focused on focal adhesions, crucial mechanotransduction elements that control myofibroblast activation (27). Knockdown of either REVERBα or TBPL1 resulted in increases of both size and number of vinculin/tensin1-positive focal-adhesion complexes (Fig. 4A and SI Appendix, Fig. S7 A–C). This increase in size suggests progression to the supermature focal adhesions involved in myofibroblast differentiation (27). In contrast, overexpression of REVERBα or TBPL1 caused the opposite effect (Fig. 4B and SI Appendix, Fig. S7 D and E). Integrinβ1, the common subunit of all collagen1-binding integrins, has previously been linked to myofibroblast activation in the liver (28), lung (29), and scleroderma (30). Knockdown of either REVERBα or TBPL1 resulted in an increase in both size and number of integrinβ1-positive focal-adhesion complexes (Fig. 4A and SI Appendix, Fig. S7A). Furthermore, knockdown of integrinβ1 prevented the induction of αSMA seen in fibroblasts cultures subjected to REVERBα knockdown (Fig. 4 C and D), highlighting the requirement for integrinβ1 for REVERBα-mediated myofibroblast activation (Fig. 4E).

Fig. 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 4.

REVERBα and TBPL1 affect myofibroblast differentiation through changes in integrinβ1 expression. (A) Representative immunofluorescent images and quantification per cell of vinculin, tensin1, and integrinβ1 following siRNA knockdown of Reverbα or Tbpl1 compared to control (nontargeting) siRNA in mLF-hT cells (n = 3 separate transfections). **P < 0.01 (1-way ANOVA post hoc Dunnett test; mean ± SEM). Dots represent individual cells from 3 transfections. cont, control siRNA; revα, Reverbα siRNA. (Scale bars, 10 µm.) (B) Representative immunofluorescence image after mLF-hT cells have been transfected with REVERBα-GFP plasmid or an empty-GFP plasmid. Cells were stained for GFP, vinculin, and nuclei (4′,6-diamidino-2-phenylindole [DAPI]) (n = 3 separate transfections). **P < 0.01 (Student t test; mean ± SEM). Dots represent individual cells from 3 transfections with the focal-adhesion number being quantified per cell. (Scale bars, 10 µm.) (C) Representative immunofluorescence images. (Scale bars, 50 µm.) (D) Quantification of the myofibroblast marker αSMA following dual siRNA knockdown (control or Reverbα in the presence or absence of Itgb1) in mLF-hT cells (n = 3 separate transfections). **P ≤ 0.01 (1-way ANOVA post hoc Dunnett test; mean ± SEM). (E) Schematic demonstrating how both REVERBα and TBPL1 regulate Integrinβ1, which in turn affects myofibroblast differentiation. ECM, extracellular matrix.

Circadian Factors Are Associated with Pulmonary Fibrosis in Humans.

Several human factors have been associated with circadian or sleep-deprivation strain, including evening chronotype, shift work, and sleep duration. We therefore investigated whether these factors were associated with pulmonary fibrosis in the UK Biobank (n = 500,074) (31). Following adjustment for known risk factors for pulmonary fibrosis (body mass index, smoking, sex, and age), short or long sleep duration (<7 h or >7 h) were associated with pulmonary fibrosis (Fig. 5A and SI Appendix, Tables S1 and S2), with the size of the odds ratio (OR) being greater than the established risk factors of age, sex, or smoking in the multivariable model. Shift work (OR: 1.353; 95% confidence interval [CI]: 1.069 to 1.710) and evening chronotype (OR: 1.040; 95% CI: 1.001 to 1.080) were also associated with pulmonary fibrosis (SI Appendix, Tables S3–S6) by a smaller degree; however, this is comparable to other diseases where these variables are risk factors (32⇓–34).

Fig. 5.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 5.

Circadian factors are associated with IPF, where a REVERB ligand represses collagen secretion. (A) Odds ratio (OR) for the association between pulmonary fibrosis and sleep duration (OR ± 95% confidence interval (CI); logistic regression; n = 500,074 subjects from the UK Biobank). (B) Changes in clock-gene expression in IPF compared to control subjects from a previously published genome array (GSE47460) (fold change ± 95% confidence interval; n = 90 controls and 98 patients with IPF). (C) qPCR for αSMA (ACTA2) and Collagen1 (COL1A1) following TGFβ stimulation (2 ng/mL) in primary human lung fibroblasts obtained from patients with pulmonary fibrosis in the presence or absence of GSK4112 (10 μM) (n = 4 fibrotic patients). *P < 0.05 (Student t test; mean ± SEM). (D) qPCR for αSMA (ACTA2) expression following treatment with TGFβ (2 ng/mL) and GSK4112 (10 μM) in human PCLS (n = 5 patients). *P < 0.05 (Student t test; mean ± SEM). (E) Enzyme-linked immunosorbent assay analysis of secreted collagen-1 in TGFβ-stimulated PCLS obtained from 3 patients with IPF treated with the REVERB ligand GSK4112 (10 μM) and an Alk5 inhibitor (1 μM) as positive control (n = 3). *P < 0.05 (paired Student t test; mean ± SEM).

Disordered Clock-Gene Expression Occurs in Idiopathic Pulmonary Fibrosis.

To look for evidence of circadian-clock disruption in IPF, we analyzed lung gene expression in a previously published microarray from the lung genomics research consortium (35). Comparison with normal lung revealed significant differences in PER1/2, CRY 2, and REVERBα/β (Fig. 5B), all encoding components of the negative-feedback arm of the core circadian clock. In addition, TBPL1 was up-regulated in pulmonary fibrosis, correlating with REVERBα expression (SI Appendix, Fig. S8A).

A REVERB Ligand Inhibits Myofibroblast Differentiation and Represses Collagen Secretion in Tissue from Pulmonary Fibrotic Patients.

Finally, we tested whether a REVERBα ligand could repress pulmonary fibrosis. The well-characterized REVERBα agonist GSK4112 (36) repressed TGFβ-induced expression of αSMA (ACTA2) and collagen-1 (COL1A1) in primary human lung fibroblasts from patients with pulmonary fibrosis (Fig. 5C). Similarly, TGFβ induction of αSMA and collagen 1 transcription was prevented by GSK4112 treatment in precision-cut human lung, organotypic slice cultures from healthy control subjects (Fig. 5D). Finally, we studied the effects of this ligand in PCLS from IPF patients along with an Alk5 inhibitor, known to inhibit Col1a1 secretion (37). GSK4112 repressed Col1a1 secretion (Fig. 5E) in a similar manner to the Alk5 inhibitor.

Discussion

Pulmonary fibrosis is an intractable and fatal disease. We have previously identified the lung as a highly circadian organ and that responses to environmental insults are regulated and shaped by the circadian clock. Therefore, we analyzed mouse lung fibrosis, finding newly-emergent, and strong circadian oscillations driven by fibroblasts. The prevalent profibrotic growth factor TGFβ was capable of transmitting timing information to recipient cells, and disruption to the core circadian clock in fibroblasts increased fibrotic response to bleomycin instillation. In vitro analysis identified a circuit linking the core clock through REVERBα, to TBPL1, and the focal adhesions important for myofibroblast activation. In human IPF lung tissue, pharmacological targeting of the clock impacted a surrogate measure of fibrotic progression, and we found an association between sleep duration, which is a product of the circadian clock, and risk of pulmonary fibrosis.

Several studies have found that circadian responses in the lung are gated through club cells (2) or macrophages (5). A previous report suggested that the acute inflammatory phase (7 d) of the bleomycin response lay under circadian control (4); therefore, we investigated circadian function in developing fibrosis. Surprisingly, there were higher-amplitude circadian oscillations in fibrotic tissue compared to normal lung tissue, but these oscillations were asynchronous, suggesting a possible role for circadian mechanisms (38). The process of fibrosis involves several different cell types including club cells, macrophages, and fibroblasts (9), but as genetic deletion of the only nonredundant circadian gene Bmal1 to the pericyte lineage stopped the emergent oscillations, the importance of fibroblasts was established. The importance of the fibroblast was further confirmed by finding that REVERBα deletion in these cells impacted the fibrotic response, but disruption in other cell types was without effect. These results build on previous discoveries showing that circadian oscillations in fibroblasts are robust (39) and alter wound-healing (40, 41).

Mechanistically, knockout or knockdown of REVERBα promoted myofibroblast activation in vitro, with the reverse effects seen with REVERBα overexpression. Analysis of REVERBα gene targets revealed striking enrichment for a single transcription factor, TBPL1, and the emergence of a coherent pathway converging on increased formation of integrinβ1 focal-adhesion complexes. To the best of our knowledge, TBPL1 has not been previously implicated in fibrotic disease, but we found its expression elevated in human IPF tissue. This and the elevated REVERBα expression are an apparent paradox, as both proteins inhibit myofibroblast activation. Therefore, we hypothesize that the increase in both TBPL1 and REVERBα in fibrotic tissue results from tissue compensation in response to fibrosis, making it a promising therapeutic pathway. Integrinβ1 emerged as the final effector, and the focal adhesions associated with it have previously been established (28) to be important for myofibroblast activation.

We have successfully used large-scale human cohorts, such as the UK Biobank, to explore connections between measures of circadian strain (shift work, chronotype, and sleep) and prevalent disease (34, 42, 43). Low-prevalence diseases such as pulmonary fibrosis present unique challenges. To address this, we identified people with pulmonary fibrosis participating in the UK Biobank (31) and linked them with information from Hospital Episode Statistic data (44). Importantly, patients were not screened for pulmonary fibrosis on enrolling in the Biobank; therefore, we cannot comment on causality, but it is clear that short sleep length is associated with pulmonary fibrosis, and this is as least as strong as existing risk factors for this disease (45), indicating potential clinical relevance. An association with long sleep duration was also found that may be biological (46) or due to confounders (47).

We, and others, have developed tool compounds capable of activating REVERBα (48, 49). These permit extension of our studies to primary human tissue, which is hard to genetically manipulate. Here, we show a marked inhibition of the myofibroblast phenotype, blunted fibrotic response to TGFβ stimulation and reduced collagen-1 secretion in IPF PCLS. We, and others, have also shown that these compounds have off-target effects (48, 50), and therefore it is reassuring that knockdown and overexpression of REVERBα in human fibroblasts had similar effects on both our mice studies and also the ligand. The recent publication (50) that the only ligand with suitable pharmacokinetics for in vivo experiments has significant off-target effects combined with the lack of translation from the mouse bleomycin model to the clinic (51) precludes an in vivo mouse experiment to confirm its therapeutic effectiveness.

Taken together, our results identify a surprising and potent role for the core circadian-clock factor REVERBα in the activation of myofibroblasts via a pathway incorporating a poorly characterized transcription factor, TBPL1, which affects the development of pulmonary fibrosis.

Methods

Mouse Lines.

mPER2::luc transgenic mice were previously described (52). The Rev-erbαfl/fl mouse (Rev-erbαDBDm) and Cre drivers targeting club cells (CCSPicre) and myeloid cells (Lysmcre) are as previously described (1). The PDGFRβcre mouse was a kind gift from N.C.H. and has been previously described (14). The Bmal1fl/fl mouse has been previously described (2).

Cell Culture.

MRC-5 cells or mLF-hT cells (16) were cultured in Dulbecco modified Eagle media.

In Vivo Bleomycin.

Male mice were challenged intratracheally with bleomycin (Sigma) or saline (vehicle).

Bioluminescence Microscopy.

Organotypic PCLS were prepared as described before (2). Bioluminescence images were obtained using a 2.5× objective (Zeiss) and captured using a cooled Andor iXon Ultra camera over a 30-min integration period.

Immunofluorescence.

For αSMA staining, cells in 35-mm dishes were fixed in 4% paraformaldehyde (PFA)/0.2% Triton X-100, followed by ice cold methanol fixation. For focal-adhesion proteins, cells were exposed to ice-cold cytoskeleton buffer (53) for 10 min followed by 4% PFA fixation for a further 10 min.

RNA Sequence.

siRNA-transfected mLF-hT and Mrc5 cells were lysed, and RNA was extracted using the ReliaPrep RNA miniprep system. RNA was sequenced on an Illumina HiSEq 4000. Analysis of these data was performed using the Ingenuity Pathway Analysis software (Qiagen).

UK Biobank.

The UK Biobank was accessed January 2019, and the data were combined with the Hospital Episode data set (54). Subjects were excluded a priori if they took sleep-altering medication or had obstructive sleep apnea.

Microarray Analysis.

Geo2R (55) was used to analyze GSE47460 generated by the Lung Genomics Research Consortium (56).

Human PCLS.

PCLS were cut at 400 µm on a vibrating microtome. TGFβ, GSK4112, or vehicle (dimethyl sulfoxide) treatments were performed each day with the slices being lysed after 4 d for qPCR analysis or 7 d for supernatant analysis. Additional methods can be found in SI Appendix.

Data Availability.

The RNA-sequence (RNA-seq) data have been deposited in the ArrayExpress Archive of Functional Genomics Data (accession no. E-MTAB-8499) (57). Matlab code for circadian analysis of Fig. 1 has been deposited in Mendeley database (doi:10.17632/5wr5s3w4s7.1) (58).

Acknowledgments

We thank Leo Zeef and Andy Hayes of the Bioinformatics and Genomic Technologies Core Facilities at the University of Manchester for providing support with regard to the RNA-seq, Joe Takahashi for providing mPER2::Luc mice, Rachel Burgoyne and Ben Barksby for help with the human PCLS, as well as the staff of the University of Manchester Histology, Bioimaging and Behavioral Sciences Facility for technical help. We thank the human study donors for their kind contribution. J.B. holds a Medical Research Council (MRC) clinician scientist award (MR/L006499/1). D.W.R. and A.S.L. both hold Wellcome Trust investigator awards (107849/A/15/Z, 107851/Z/15/Z), and D.W.R. is supported by an MRC program grant (MR/P023576/1). J.E.G. has an Arthritis Research Career Development Fellowship (Reference 20629), and H.J.D. is supported by an Asthma UK Senior Clinical Academic Development Award (AUK-SCAD-2013-229). J.B. and G.B.K. are supported by a National Institute of Academic Anaesthesia grant (WKR0-2019-0037). G.B.K. is supported by an MRC clinical research training fellowship (MR/N002024/1). The research of B.H. is supported by a foundation grant from the Canadian Institutes of Health Research and infrastructure grants from the Canadian Foundation for Innovation and Ontario Research Funds. N.C.H. is supported by a Wellcome Trust Senior Research Fellowship in Clinical Science (ref. 103749). L.A.B. is supported by an MRC Industry Collaboration Agreement award (MR/R023026/1). A.J.F. is funded by the National Institute for Health Research (NIHR) Blood and Transplant Research Unit in Organ Donation and Transplantation at Newcastle University and in partnership with National Health Service (NHS) Blood and Transplant. The Manchester Allergy, Respiratory and Thoracic Surgery Biobank is supported by the North West Lung Centre Charity and NIHR Clinical Research Facility at Manchester University NHS Foundation Trust. This research was also supported by the NIHR Manchester Biomedical Research Centre.

Footnotes

  • ↵1P.S.C. and P.M. contributed equally to this work.

  • ↵2To whom correspondence may be addressed. Email: john.blaikley{at}manchester.ac.uk.
  • Author contributions: P.S.C., P.M., A.N., M.L., K.P.-H., A.J.F., R.C.C., B.H., D.W.R., and J.F.B. designed research; P.S.C., P.M., A.N., S.G.A., L.A.B., J.B., G.B.K., N.B., P.F.M., H.J.D., D.A.B., J.E.G., A.S.L., and J.F.B. performed research; M.L., R.V.V., R.S., and N.C.H. contributed new reagents/analytic tools; P.S.C., P.M., A.N., S.G.A., L.A.B., P.F.M., M.K.R., and J.F.B. analyzed data; and P.S.C., P.M., A.N., S.G.A., N.C.H., K.P.-H., A.J.F., R.C.C., D.A.B., J.E.G., A.S.L., M.K.R., B.H., D.W.R., and J.F.B. wrote the paper.

  • The authors declare no competing interest.

  • This article is a PNAS Direct Submission.

  • Data deposition: The RNA-seq data reported in this paper have been deposited in the ArrayExpress Archive of Functional Genomics Data, https://www.ebi.ac.uk/arrayexpress (accession no. E-MTAB-8499). The Matlab code for circadian analysis of Fig. 1 has been deposited in Mendeley database (doi:10.17632/5wr5s3w4s7.1).

  • This article contains supporting information online at https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1912109117/-/DCSupplemental.

  • Copyright © 2020 the Author(s). Published by PNAS.

This open access article is distributed under Creative Commons Attribution License 4.0 (CC BY).

References

  1. ↵
    1. M. Pariollaud et al
    ., Circadian clock component REV-ERBα controls homeostatic regulation of pulmonary inflammation. J. Clin. Invest. 128, 2281–2296 (2018).
    OpenUrl
  2. ↵
    1. J. Gibbs et al
    ., An epithelial circadian clock controls pulmonary inflammation and glucocorticoid action. Nat. Med. 20, 919–926 (2014).
    OpenUrlCrossRefPubMed
  3. ↵
    1. P. S. Cunningham et al
    ., Incidence of primary graft dysfunction after lung transplantation is altered by timing of allograft implantation. Thorax 74, 413–416 (2019).
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. V. Pekovic-Vaughan et al
    ., The circadian clock regulates rhythmic activation of the NRF2/glutathione-mediated antioxidant defense pathway to modulate pulmonary fibrosis. Genes Dev. 28, 548–560 (2014).
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. J. E. Gibbs et al
    ., The nuclear receptor REV-ERBα mediates circadian regulation of innate immunity through selective regulation of inflammatory cytokines. Proc. Natl. Acad. Sci. U.S.A. 109, 582–587 (2012).
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. J. E. Gibbs et al
    ., Circadian timing in the lung; a specific role for bronchiolar epithelial cells. Endocrinology 150, 268–276 (2009).
    OpenUrlCrossRefPubMed
  7. ↵
    1. ATS Assembly on Respiratory Cell and Molecular Biology
    1. R. G. Jenkins et al
    .; ATS Assembly on Respiratory Cell and Molecular Biology, An official american thoracic society workshop report: Use of animal models for the preclinical assessment of potential therapies for pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 56, 667–679 (2017).
    OpenUrlCrossRef
  8. ↵
    1. V. Cottin et al
    ., Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur. Respir. Rev. 27, 180076 (2018).
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. L. Richeldi,
    2. H. R. Collard,
    3. M. G. Jones
    , Idiopathic pulmonary fibrosis. Lancet 389, 1941–1952 (2017).
    OpenUrlCrossRefPubMed
  10. ↵
    1. A. Pardo,
    2. M. Selman
    , Lung fibroblasts, aging, and idiopathic pulmonary fibrosis. Ann. Am. Thorac. Soc. 13 (suppl. 5), S417–S421 (2016).
    OpenUrlCrossRefPubMed
  11. ↵
    1. B. Hinz
    , Mechanical aspects of lung fibrosis: A spotlight on the myofibroblast. Proc. Am. Thorac. Soc. 9, 137–147 (2012).
    OpenUrlCrossRefPubMed
  12. ↵
    1. S. I. Nureki et al
    ., Expression of mutant Sftpc in murine alveolar epithelia drives spontaneous lung fibrosis. J. Clin. Invest. 128, 4008–4024 (2018).
    OpenUrl
  13. ↵
    1. A. Moeller et al
    ., Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 179, 588–594 (2009).
    OpenUrlCrossRefPubMed
  14. ↵
    1. N. C. Henderson et al
    ., Targeting of αv integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat. Med. 19, 1617–1624 (2013).
    OpenUrlCrossRefPubMed
  15. ↵
    1. G. Burgstaller et al
    ., The instructive extracellular matrix of the lung: Basic composition and alterations in chronic lung disease. Eur. Respir. J. 50, 1601805 (2017).
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. M. Lodyga et al
    ., Cadherin-11-mediated adhesion of macrophages to myofibroblasts establishes a profibrotic niche of active TGF-β. Sci. Signal. 12, eaao3469 (2019).
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. J. S. Takahashi
    , Transcriptional architecture of the mammalian circadian clock. Nat. Rev. Genet. 18, 164–179 (2017).
    OpenUrlCrossRefPubMed
  18. ↵
    1. M. Hatori et al
    ., Time-restricted feeding without reducing caloric intake prevents metabolic diseases in mice fed a high-fat diet. Cell Metab. 15, 848–860 (2012).
    OpenUrlCrossRefPubMed
  19. ↵
    1. S. N. Archer,
    2. C. Schmidt,
    3. G. Vandewalle,
    4. D. J. Dijk
    , Phenotyping of PER3 variants reveals widespread effects on circadian preference, sleep regulation, and health. Sleep Med. Rev. 40, 109–126 (2018).
    OpenUrl
  20. ↵
    1. K. Man,
    2. A. Loudon,
    3. A. Chawla
    , Immunity around the clock. Science 354, 999–1003 (2016).
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. A. C. West et al
    ., Misalignment with the external light environment drives metabolic and cardiac dysfunction. Nat. Commun. 8, 417 (2017).
    OpenUrl
  22. ↵
    1. L. Kervezee,
    2. N. Cermakian,
    3. D. B. Boivin
    , Individual metabolomic signatures of circadian misalignment during simulated night shifts in humans. PLoS Biol. 17, e3000303 (2019).
    OpenUrl
  23. ↵
    1. M. K. Bunger et al
    ., Mop3 is an essential component of the master circadian pacemaker in mammals. Cell 103, 1009–1017 (2000).
    OpenUrlCrossRefPubMed
  24. ↵
    1. L. Plantier et al
    ., Physiology of the lung in idiopathic pulmonary fibrosis. Eur. Respir. Rev. 27, 170062 (2018).
    OpenUrlAbstract/FREE Full Text
  25. ↵
    1. N. Yang et al
    ., Cellular mechano-environment regulates the mammary circadian clock. Nat. Commun. 8, 14287 (2017).
    OpenUrlCrossRef
  26. ↵
    1. Y. Zhang et al
    ., GENE REGULATION. Discrete functions of nuclear receptor Rev-erbα couple metabolism to the clock. Science 348, 1488–1492 (2015).
    OpenUrlAbstract/FREE Full Text
  27. ↵
    1. B. Hinz
    , Masters and servants of the force: The role of matrix adhesions in myofibroblast force perception and transmission. Eur. J. Cell Biol. 85, 175–181 (2006).
    OpenUrlCrossRefPubMed
  28. ↵
    1. K. Martin et al
    ., PAK proteins and YAP-1 signalling downstream of integrin beta-1 in myofibroblasts promote liver fibrosis. Nat. Commun. 7, 12502 (2016).
    OpenUrlCrossRefPubMed
  29. ↵
    1. N. I. Reed et al
    ., The αvβ1 integrin plays a critical in vivo role in tissue fibrosis. Sci. Transl. Med. 7, 288ra79 (2015).
    OpenUrlAbstract/FREE Full Text
  30. ↵
    1. E. E. Gerber et al
    ., Integrin-modulating therapy prevents fibrosis and autoimmunity in mouse models of scleroderma. Nature 503, 126–130 (2013).
    OpenUrlCrossRefPubMed
  31. ↵
    1. R. Collins
    , What makes UK Biobank special? Lancet 379, 1173–1174 (2012).
    OpenUrlCrossRefPubMed
  32. ↵
    1. Z. Shan et al
    ., Sleep duration and risk of type 2 diabetes: A meta-analysis of prospective studies. Diabetes Care 38, 529–537 (2015).
    OpenUrlAbstract/FREE Full Text
  33. ↵
    1. K. L. Knutson,
    2. M. von Schantz
    , Associations between chronotype, morbidity and mortality in the UK Biobank cohort. Chronobiol. Int. 35, 1045–1053 (2018).
    OpenUrlCrossRefPubMed
  34. ↵
    1. C. Vetter et al
    ., Night shift work, genetic risk, and type 2 diabetes in the UK Biobank. Diabetes Care 41, 762–769 (2018).
    OpenUrlAbstract/FREE Full Text
  35. ↵
    1. Y. Bauer et al
    ., A novel genomic signature with translational significance for human idiopathic pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 52, 217–231 (2015).
    OpenUrlCrossRefPubMed
  36. ↵
    1. Q. J. Meng et al
    ., Ligand modulation of REV-ERBalpha function resets the peripheral circadian clock in a phasic manner. J. Cell Sci. 121, 3629–3635 (2008).
    OpenUrlAbstract/FREE Full Text
  37. ↵
    1. P. Bonniaud et al
    ., Progressive transforming growth factor beta1-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor. Am. J. Respir. Crit. Care Med. 171, 889–898 (2005).
    OpenUrlCrossRefPubMed
  38. ↵
    1. A. Gerber et al
    ., Blood-borne circadian signal stimulates daily oscillations in actin dynamics and SRF activity. Cell 152, 492–503 (2013).
    OpenUrlCrossRefPubMed
  39. ↵
    1. A. Balsalobre,
    2. F. Damiola,
    3. U. Schibler
    , A serum shock induces circadian gene expression in mammalian tissue culture cells. Cell 93, 929–937 (1998).
    OpenUrlCrossRefPubMed
  40. ↵
    1. N. P. Hoyle et al
    ., Circadian actin dynamics drive rhythmic fibroblast mobilization during wound healing. Sci. Transl. Med. 9, eaal2774 (2017).
    OpenUrlAbstract/FREE Full Text
  41. ↵
    1. E. Kowalska et al
    ., NONO couples the circadian clock to the cell cycle. Proc. Natl. Acad. Sci. U.S.A. 110, 1592–1599 (2013).
    OpenUrlAbstract/FREE Full Text
  42. ↵
    1. S. E. Jones et al
    ., Genome-wide association analyses of chronotype in 697,828 individuals provides insights into circadian rhythms. Nat. Commun. 10, 343 (2019).
    OpenUrlCrossRefPubMed
  43. ↵
    1. HUNT All In Sleep
    1. J. M. Lane et al
    .; HUNT All In Sleep, Biological and clinical insights from genetics of insomnia symptoms. Nat. Genet. 51, 387–393 (2019).
    OpenUrl
  44. ↵
    1. J. C. Thorn et al
    ., Validation of the hospital episode statistics outpatient dataset in England. Pharmacoeconomics 34, 161–168 (2016).
    OpenUrlCrossRefPubMed
  45. ↵
    1. ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis
    1. G. Raghu et al
    .; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis, An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 183, 788–824 (2011).
    OpenUrlCrossRefPubMed
  46. ↵
    1. M. A. Grandner,
    2. S. P. Drummond
    , Who are the long sleepers? Towards an understanding of the mortality relationship. Sleep Med. Rev. 11, 341–360 (2007).
    OpenUrlCrossRefPubMed
  47. ↵
    1. M. Jike,
    2. O. Itani,
    3. N. Watanabe,
    4. D. J. Buysse,
    5. Y. Kaneita
    , Long sleep duration and health outcomes: A systematic review, meta-analysis and meta-regression. Sleep Med. Rev. 39, 25–36 (2018).
    OpenUrl
  48. ↵
    1. R. P. Trump et al
    ., Optimized chemical probes for REV-ERBα. J. Med. Chem. 56, 4729–4737 (2013).
    OpenUrlCrossRefPubMed
  49. ↵
    1. L. A. Solt et al
    ., Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists. Nature 485, 62–68 (2012).
    OpenUrlCrossRefPubMed
  50. ↵
    1. P. Dierickx et al
    ., SR9009 has REV-ERB-independent effects on cell proliferation and metabolism. Proc. Natl. Acad. Sci. U.S.A. 116, 12147–12152 (2019).
    OpenUrlAbstract/FREE Full Text
  51. ↵
    1. R. Carrington,
    2. S. Jordan,
    3. S. C. Pitchford,
    4. C. P. Page
    , Use of animal models in IPF research. Pulm. Pharmacol. Ther. 51, 73–78 (2018).
    OpenUrl
  52. ↵
    1. S. H. Yoo et al
    ., PERIOD2:LUCIFERASE real-time reporting of circadian dynamics reveals persistent circadian oscillations in mouse peripheral tissues. Proc. Natl. Acad. Sci. U.S.A. 101, 5339–5346 (2004).
    OpenUrlAbstract/FREE Full Text
  53. ↵
    1. J. Smith-Clerc,
    2. B. Hinz
    , Immunofluorescence detection of the cytoskeleton and extracellular matrix in tissue and cultured cells. Methods Mol. Biol. 611, 43–57 (2010).
    OpenUrlCrossRefPubMed
  54. ↵
    1. A. Herbert,
    2. L. Wijlaars,
    3. A. Zylbersztejn,
    4. D. Cromwell,
    5. P. Hardelid
    , Data resource profile: Hospital episode statistics admitted patient care (HES APC). Int. J. Epidemiol. 46, 1093–1093i (2017).
    OpenUrlCrossRefPubMed
  55. ↵
    1. T. Barrett et al
    ., NCBI GEO: Archive for functional genomics data sets–Update. Nucleic Acids Res. 41, D991–D995 (2013).
    OpenUrlCrossRefPubMed
  56. ↵
    1. G. Yu et al
    ., Thyroid hormone inhibits lung fibrosis in mice by improving epithelial mitochondrial function. Nat. Med. 24, 39–49 (2018).
    OpenUrlCrossRef
  57. ↵
    1. P. Cunningham,
    2. J. Blaikley
    , RNA-seq analysis following REVERBalpha knockdown in fibroblasts. Array Express. http://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-8499. Accessed 12 December 2019.
  58. ↵
    1. J. Blaikley
    , The circadian clock protein REVERBα inhibits pulmonary fibrosis development, Mendeley, http://dx.doi.org/10.17632/5wr5s3w4s7.1 Accessed 12 December 2019.
PreviousNext
Back to top
Article Alerts
Email Article

Thank you for your interest in spreading the word on PNAS.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The circadian clock protein REVERBα inhibits pulmonary fibrosis development
(Your Name) has sent you a message from PNAS
(Your Name) thought you would like to see the PNAS web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The circadian clock protein REVERBα inhibits pulmonary fibrosis development
Peter S. Cunningham, Peter Meijer, Alicja Nazgiewicz, Simon G. Anderson, Lee A. Borthwick, James Bagnall, Gareth B. Kitchen, Monika Lodyga, Nicola Begley, Rajamiyer V. Venkateswaran, Rajesh Shah, Paul F. Mercer, Hannah J. Durrington, Neil C. Henderson, Karen Piper-Hanley, Andrew J. Fisher, Rachel C. Chambers, David A. Bechtold, Julie E. Gibbs, Andrew S. Loudon, Martin K. Rutter, Boris Hinz, David W. Ray, John F. Blaikley
Proceedings of the National Academy of Sciences Jan 2020, 117 (2) 1139-1147; DOI: 10.1073/pnas.1912109117

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
The circadian clock protein REVERBα inhibits pulmonary fibrosis development
Peter S. Cunningham, Peter Meijer, Alicja Nazgiewicz, Simon G. Anderson, Lee A. Borthwick, James Bagnall, Gareth B. Kitchen, Monika Lodyga, Nicola Begley, Rajamiyer V. Venkateswaran, Rajesh Shah, Paul F. Mercer, Hannah J. Durrington, Neil C. Henderson, Karen Piper-Hanley, Andrew J. Fisher, Rachel C. Chambers, David A. Bechtold, Julie E. Gibbs, Andrew S. Loudon, Martin K. Rutter, Boris Hinz, David W. Ray, John F. Blaikley
Proceedings of the National Academy of Sciences Jan 2020, 117 (2) 1139-1147; DOI: 10.1073/pnas.1912109117
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Mendeley logo Mendeley

Article Classifications

  • Biological Sciences
  • Medical Sciences
Proceedings of the National Academy of Sciences: 117 (2)
Table of Contents

Submit

Sign up for Article Alerts

Jump to section

  • Article
    • Abstract
    • Results
    • Discussion
    • Methods
    • Acknowledgments
    • Footnotes
    • References
  • Figures & SI
  • Info & Metrics
  • PDF

You May Also be Interested in

Smoke emanates from Japan’s Fukushima nuclear power plant a few days after tsunami damage
Core Concept: Muography offers a new way to see inside a multitude of objects
Muons penetrate much further than X-rays, they do essentially zero damage, and they are provided for free by the cosmos.
Image credit: Science Source/Digital Globe.
Water from a faucet fills a glass.
News Feature: How “forever chemicals” might impair the immune system
Researchers are exploring whether these ubiquitous fluorinated molecules might worsen infections or hamper vaccine effectiveness.
Image credit: Shutterstock/Dmitry Naumov.
Venus flytrap captures a fly.
Journal Club: Venus flytrap mechanism could shed light on how plants sense touch
One protein seems to play a key role in touch sensitivity for flytraps and other meat-eating plants.
Image credit: Shutterstock/Kuttelvaserova Stuchelova.
Illustration of groups of people chatting
Exploring the length of human conversations
Adam Mastroianni and Daniel Gilbert explore why conversations almost never end when people want them to.
Listen
Past PodcastsSubscribe
Horse fossil
Mounted horseback riding in ancient China
A study uncovers early evidence of equestrianism in ancient China.
Image credit: Jian Ma.

Similar Articles

Site Logo
Powered by HighWire
  • Submit Manuscript
  • Twitter
  • Facebook
  • RSS Feeds
  • Email Alerts

Articles

  • Current Issue
  • Special Feature Articles – Most Recent
  • List of Issues

PNAS Portals

  • Anthropology
  • Chemistry
  • Classics
  • Front Matter
  • Physics
  • Sustainability Science
  • Teaching Resources

Information

  • Authors
  • Editorial Board
  • Reviewers
  • Subscribers
  • Librarians
  • Press
  • Cozzarelli Prize
  • Site Map
  • PNAS Updates
  • FAQs
  • Accessibility Statement
  • Rights & Permissions
  • About
  • Contact

Feedback    Privacy/Legal

Copyright © 2021 National Academy of Sciences. Online ISSN 1091-6490